Relmada Therapeutics Files 8-K
Ticker: RLMD · Form: 8-K · Filed: Dec 4, 2024 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Relmada filed a routine 8-K on Dec 4th, no major news.
AI Summary
Relmada Therapeutics, Inc. filed an 8-K on December 4, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements.
Why It Matters
This filing indicates standard corporate reporting activity for Relmada Therapeutics, Inc., without disclosing new material information that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not contain any new material information or significant financial disclosures.
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — Registrant
- December 4, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 2222 Ponce de Leon Blvd. , Floor 3 Coral Gables , FL 33134 (address) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Relmada Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as indicated by the filing's item information.
On what date was this 8-K filing reported?
The filing was reported on December 4, 2024, which is also the date of the earliest event reported.
In which U.S. state is Relmada Therapeutics, Inc. incorporated?
Relmada Therapeutics, Inc. is incorporated in Nevada.
What is the principal executive office address for Relmada Therapeutics, Inc.?
The principal executive office address is 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134.
Does this 8-K filing disclose any specific new financial results or material events?
Based on the provided text, this 8-K filing is for standard reporting purposes (Regulation FD Disclosure, Financial Statements and Exhibits) and does not appear to disclose specific new financial results or material events.
Filing Stats: 605 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-12-04 07:30:15
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The Nasdaq
Filing Documents
- ea0223563-8k_relmada.htm (8-K) — 28KB
- ea022356301ex99-1_relmada.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-24-105245.txt ( ) — 218KB
- rlmd-20241204.xsd (EX-101.SCH) — 3KB
- rlmd-20241204_lab.xml (EX-101.LAB) — 33KB
- rlmd-20241204_pre.xml (EX-101.PRE) — 22KB
- ea0223563-8k_relmada_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 4, 2024, Relmada Therapeutics, Inc. (the "Company"), issued a press release announcing that the pre-planned interim analysis of Reliance II, conducted by an independent Data Monitoring Committee, indicated that the Company's Reliance II Phase 3 study is futile and is unlikely to meet the primary efficacy endpoint with statistical significance. Reliance II is designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder (MDD), to be used in combination with other approved anti-depressants. No new safety signals were reported. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be "furnished" and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), regardless of any general incorporation language in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued on December 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 4, 2024 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 2